Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fated dogs: Effect of somatostatin infusion or pretreatment with pirenzepine

Journal of Endocrinology

Volumn 156, Issue 2, 1998, Pages 341-348

  Rigamonti, A E ^a   Marazzi, N ^a   Cella, S G ^a   Cattaneo, L ^a   Muller E E ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEXARELIN; PIRENZEPINE; SOMATOSTATIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOG; FEEDING; FEMALE; HORMONE RESPONSE; MALE; METABOLIC CLEARANCE RATE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; MALE; METABOLIC CLEARANCE RATE; MUSCARINIC ANTAGONISTS; OLIGOPEPTIDES; PIRENZEPINE; RADIOIMMUNOASSAY; SOMATOSTATIN;

EID: 0031882620     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1560341     Document Type: Article

References (50)

1. Akman MS, Gifard M, O'Brien LF, Ho AK & Chik CL 1993 Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2) in rat anterior pituitary cells Endocrinology 132 1286-1291.
2. Arce V, Cella SG, Locatelli V & Müller EE 1991 Studies of growth hormone secretion in calorically restricted dogs: effect of cholinergic agonists and antagonists, glucose and thyrotrophin-releasing hormone. Neuroendocrinology 53 467-472.
3. Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F & Ghigo E 1995 Modulation of growth hormone-releasing activity of hexarelin in man. Neuroendocrinology 61 51-56.
4. Blackard WG & Waddel CC 1969 Cholinergic blockade and growth hormone responsiveness to insulin hypoglycemia. Proceedings of the Society for Experimental Biology and Medicine 131 192-196.
5. Bowers CY, Momany FA, Reynolds GA & Hong A 1984 On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114 1537-1545.
6. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS & Thorner MO 1990 Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism 70 975-982.
7. Bowers CY, Sartor AO, Reynolds GA & Badger TM 1991 On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 128 2027-2035.
8. Bowers CY, Alster DK & Frentz JM 1992 The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. Journal of Clinical Endocrinology and Metabolism 74 292-298.
9. Bruno JF, Xu Y, Song J & Berelowitz M 1994 Pituitary and hypothalamic somatostatin receptor subtype messenger ribonucleic acid expression in the food-deprived and diabetic rat. Endocrinology 135 1787-1792.
10. Busby WH, Snyder DK & Clemmȯns DR 1988 Radioimmunoassay of 26 000-dalton plasma insulin-like growth factor-binding protein: control by nutritional variables. Journal of Clinical Endocrinology and Metabolism 67 1225-1230.
11. Casanueva FF, Betti R, Cella SG & Müller EE 1983 Effect of agonists and antagonists of cholinergic neurotransmission on growth hormone release in the dog. Acta Endocrinologica 103 15-20.
12. Casanueva FF, Villenueva L, Cabranes JA, Cabezas-Cerrato J & Fernandez-Cruz A 1984 Cholinergic mediation of growth hormone secretion elicited by arginine, clonidine and physical exercise in man. Journal of Clinical Endocrinology and Metabolism 59 526-530.
13. Cella SG, Moiraghi V, Minuto F, Barreca A, Cocchi D, De Gennaro Colonna V, Reina G & Müller EE 1989 Prolonged fasting or clonidine can restore the defective growth hormone secretion in old dogs. Acta Endocrinologica 121 177-184.
14. Cella SG, Locatelli V, Poratelli M, De Gennaro Colonna V, Imbimbo BP, Deghenghi R & Müller EE 1995 Hexarelin, a potent GHRP analogue: interactions with GHRH and clonidine in young and aged dogs. Peptides 16 81-86.
15. Cella SG, Luceri M, Cattaneo L, Torsello A & Müller EE 1996a Somatostatin withdrawal as generator of pulsatile GH release in the dog: a possible tool to evaluate the endogenous GHRH tone? Neuroendocrinology 3 481-488.
16. Cella SG, Cerri CG, Daniel S, Sibilia V, Rigamonti A, Cattaneo L, Deghenghi R & Müller EE 1996b Sixteen weeks of hexarelin therapy in aged dogs: effect on the somatotropic axis, muscle morphology, and bone metabolism. Journal of Gerontology 51 439-447.
17. Deghenghi R, Cananzi MM, Torsello A, Battisti C, Müller EE & Locatelli V 1994 GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences 54 1321-1328.
18. Foppiani L, Giusti M, Cuttica CM, Falivene MR, Valenti S & Giordano G 1996 Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa. In Abstract Book of the International Congress of Endocrinology, June 12-15 1996, San Francisco, USA. Abstract P1-606, 286.
19. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R & Camanni F 1994 Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, and oral administration in man. Journal of Clinical Endocrinology and Metabolism 78 693-698.
20. Goth MI, Lyons CE, Canny BJ & Thorner MO 1992 Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 130 939-944.
21. Hartman ML, Farello G, Pezzoli SS & Thorner MO 1992a Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. Journal of Clinical Endocrinology and Metabolism 74 1378-1384.
22. Hartman M, Veldhuis JD, Johnson MI, Lee MM, Alberti KGMM, Samojlik E & Thorner MO 1992b Augmented GH secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. Journal of Clinical Endocrinology and Metabolism 74 757-765.
23. Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KG & Thorner MO 1988 Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. Journal of Clinical Investigation 81 968-975.
24. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hrzeniuk DL, Palyha OC, Anderson J et al. 1996 A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273 974-977.
25. Ilson BE, Jorkasky DK, Curnow RT & Stote RM 1989 Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. Journal of Clinical Endocrinology and Metabolism 69 212-214.
26. Korbonits M & Grossman AB 1995 Growth hormone-releasing peptide and its analogues. Trends in Endocrinology and Metabolism 6 43-49.
27. Locatelli V, Torsello A, Redaelli M, Ghigo E, Massara F & Müller EE 1986 Cholinergic agonist drugs modulate the growth hormone response to growth hormone releasing hormone in the rat: evidence for mediation by somatostatin. Journal of Endocrinology 111 271-275.
28. 2+]) and GH release from purified rat somatotrophs. Endocrinology 128 592-603.
29. Magnan E, Cataldi M, Guillaume V, Mazzocchi I, Dutour A, Conte-Devolx B, Giraud P & Oliver C 1993 Neostigmine stimulates growth hormone releasing hormone release into hypophysial portal blood of conscious sheep. Endocrinology 132 1247-1251.
30. Magnan E, Mazzocchi I, Cataldi M, Guillaume V, Dutour A, Dadoun F, Le Bouc Y, Sauze N, Renard M, Conte-Devolx B & Oliver C 1995 Effect of actively immunizing sheep against growth hormone-releasing hormone or somatostatin on spontaneous pulsatile and neostigmine-induced growth hormone secretion. Journal of Endocrinology 144 83-90.
31. Massara F, Ghigo E, Goffi S, Molinatti G, Müller EE & Camanni F 1984 Blockade of hp-GRF-40-induced GH release in normal men by a cholinergic muscarinic antagonist. Journal of Clinical Endocrinology and Metabolism 59 1025-1027.
32. Massara F, Ghigo E, Molinatti P, Mazza E, Locatelli V, Müller EE & Camanni F 1986 Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man. Acta Endocrinologica 113 12-16.
33. Meister B 1989 In Hypothalamic Neurosecretory Neurons. Histochemical and Experimental Studies on Distribution and Regulation with Special Reference to Multiple Messenger Systems. PhD Thesis, pp 600-601. Stockholm.
34. Molla F, Alvarez CV, Benitez L, Burguera B, Coya R, Casanueva FF & Dieguez C 1993 Regulation of His-dTrp-Ala-Trp-dPhe-Lys-NH2 (GHRP-6)-induced GH secretion in the rat. Neuroendocrinology 57 247-256.
35. Müller EE 1987 Neural control of somatotropic function. Physiological Reviews 67 962-1053.
36. Müller EE, Rolla M, Ghigo E, Belliti D, Arvat E, Andreoni A, Torsello A, Locatelli V & Camanni F 1995 Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Drugs 50 805-837.
37. Murphy LJ, Seneviratne C, Moreira P & Reid RE 1991 Enhanced expression of insulin-like growth factor-binding protein-1 in the fasted rat: the effects of insulin and growth hormone administration. Endocrinology 128 689-696.
38. Peñalva A, Carballo A, Pombo M, Casanueva FF & Dieguez C 1993 Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycaemia on GHRP-6-induced secretion in man. Journal of Clinical Endocrinology and Metabolism 76 168-171.
39. Rolla M, Andreoni A, Belliti D, Ceragioli MR & Paolicchi R 1986 Evaluation of growth hormone response to growth hormone-releasing factor in patients with anorexia nervosa. Psychiatry Research 16 Suppl 92.
40. Rolla M, Andreoni A, Belliti D, Cristofani R, Ferdeghini M & Müller EE 1991 Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute recovery phase of anorexia nervosa and atypical eating disorders. Biological Psychiatry 29 1079-1091.
41. Ross RJM, Tsagarakis S, Grossman A, Nhagafoong L, Tozel RJ, Rees LM & Besser GM 1987 GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH. Clinical Endocrinology 27 727-732.
42. Scacchi M, Pincelli AI, Danesi & Cavagnini F 1996 Growth hormone releasing activity of hexarelin in anorexia nervosa. In Abstract Book of the International Congress of Endocrinology, June 12-15 1996, San Francisco, USA. Abstract P3-66, 771.
43. Srikant CB & Patel YC 1982 Characterization of pituitary membrane receptors for somatostatin in the rat. Endocrinology 110 2138-2144.
44. Tait PG 1963 The use of isotopic steroids for measurement of production rates in vivo. Journal of Clinical Endocrinology 23 1287-1297.
45. Tamai H, Komaki G, Matsubayashi S, Kobayashi N, Mori K, Nakagawa T, Truong MP, Walter RM Jr & Kumagai LF 1990 Effect of cholinergic muscarinic receptor blockade of human growth hormone (GH)-releasing hormone (1-44)-induced GH secretion in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 70 738-741.
46. Tannenbaum GS & Rorstad O 1979 Effect of prolonged food deprivation on the ultradian growth hormone rhythm and immunoreactive somatostatin tissue levels in the rat. Endocrinology 104 1733-1738.
47. Tannenbaum GS, Painson JC, Lengyel AM & Brazeau P 1989 Paradoxical enhancement of pituitary growth hormone (GH) responsiveness to GH-releasing factor in the face of high somatostatin tone. Endocrinology 124 1380-1388.
48. Torsello A, Panzeri G, Cermenati P, Caroleo MC, Ghigo E, Camanni F & Müller EE 1988 Involvement of somatostatin and cholinergic system in the mechanisms of growth hormone autofeedback regulation in the rat. Journal of Endocrinology 117 273-281.
49. Walker RF, Codd EE, Barone FC, Nelson AH, Goodwin T & Campbell SA 1990 Oral activity of the growth hormone releasing peptide His-DTrp-Ala-Trp-DPhe-Lys-NH2 in rat, dogs, monkey. Life Sciences 47 29-36.
50. 3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes. Life Sciences 32 3001-3011.